CD34+ immunoselection of autologous grafts for the treatment of high-risk neuroblastoma

Pediatric Blood and Cancer

Volumn 56, Issue 1, 2011, Pages 134-142

  Marabelle, Aurélien ^a,b   Merlin, Etienne ^b,c,d   Halle, Pascale ^b,c   Paillard, Catherine ^b,c   Berger, Marc ^b,d   Tchirkov, Andrei ^b,d   Rousseau, Raphaël ^a,e   Leverger, Guy ^f   Piguet, Christophe ^g   Stephan, Jean Louis ^h   Demeocq, François ^b,c,d   Kanold, Justyna ^b,c,d  

^a CENTRE LÉON BÉRARD   (France)

^b HÔTEL DIEU   (France)

^c INSERM   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

^e UNIVERSITÉ LYON 1   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g LIMOGES UNIVERSITY HOSPITAL   (France)

^h UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

Author keywords

Antigens; CD34; Hematopoietic stem cell transplantation; Immunomagnetic separation; Neuroblastoma; Peripheral blood stem cell transplantation

Indexed keywords

BUSULFAN; MELPHALAN;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CD34 SELECTION; CHILD; CLINICAL ARTICLE; DRUG MEGADOSE; EVENT FREE SURVIVAL; HERPES ZOSTER; HUMAN; INFANT; LEUKAPHERESIS; NEUROBLAST; NEUROBLASTOMA; NEWBORN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PYELONEPHRITIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SEPSIS;

EID: 78649654337     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22840     Document Type: Article

References (59)

1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 1999; 341: 1165-1173.
2. Moss TJ, Cairo M, Santana VM, et al. Clonogenicity of circulating neuroblastoma cells: Implications regarding peripheral blood stem cell transplantation. Blood 1994; 83: 3085-3089.
3. Rill D, Santana V, Roberts W, et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994; 84: 380-383.
4. Moss T, Cairo M, Santana V, et al. Clonogenicity of circulating neuroblastoma cells: Implications regarding peripheral blood stem cell transplantation. Blood 1994; 83: 3085-3089.
5. Kushner BH, Gulati SC, Kwon JH, et al. High-dose melphalan with 6-hydroxydopamine-purged autologous bone marrow transplantation for poor-risk neuroblastoma. Cancer 1991; 68: 242-247.
6. Hartmann O, Valteau-Couanet D, Benhamou E, et al. Stage IV neuroblastoma in patients over 1 year of age at diagnosis: Consolidation of poor responders with combined busulfan, cyclophosphamide and melphalan followed by in vitro mafosfamide-purged autologous bone marrow transplantation. Eur J Cancer 1997; 33: 2126-2129.
7. Treleaven JG, Ugelstad J, Philip T, et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 323: 70-73.
8. Kemshead JT, Heath L, Gibson FM, et al. Magnetic microspheres and monoclonal antibodies for the depletion of neuroblastoma cells from bone marrow: Experiences, improvements and observations. Br J Cancer 1986; 54: 771-778.
9. Reynolds CP, Seeger RC, Vo DD, et al. Model system for removing neuroblastoma cells from bone marrow using monoclonal antibodies and magnetic immunobeads. Cancer Res 1986; 46: 5882-5886.
10. Wagner LM, Guichard SM, Burger RA, et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: Preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002; 62: 5001-5007.
11. Civin CI, Trischmann T, Kadan NS, et al. Highly purified CD34-positive cells reconstitute hematopoiesis. J Clin Oncol 1996; 14: 2224-2233.
12. Kanold J, Berger M, Rapatel C, et al. CD34+ cell immunoselection from G-CSF-alone-primed peripheral blood in children with low body mass. Br J Haematol 1995; 91: 431-433.
13. Berger M, Kanold J, Rapatel C, et al. Feasibility of a PB CD34+ cell transplantation procedure using standard leukapheresis products in very small children. Bone Marrow Transplant 1997; 20: 191-198.
14. Tchirkov A, Kanold J, Giollant M, et al. Molecular monitoring of tumor cell contamination in leukapheresis products from stage IV neuroblastoma patients before and after positive CD34 selection. Med Pediatr Oncol 1998; 30: 228-232.
15. Kanold J, Halle P, Rapatel C, et al. Safe and efficient peripheral blood stem cell collection in the smallest of children. Ther Apher 1998; 2: 49-57.
16. Merlin E, Piguet C, Auvrignon A, et al. The pros and cons of split-dose granulocyte colony-stimulating factor alone rather than a single high dose for hematopoietic progenitor cell mobilization in small children (<15kg) with solid tumors. Haematologica 2006; 91: 1004-1005.
17. Kanold J, Halle P, Berger M, et al. Large-volume leukapheresis procedure for peripheral blood progenitor cell collection in children weighing 15 kg or less: Efficacy and safety evaluation. Med Pediatr Oncol 1999; 32: 7-10.
18. Schumm M, Lang P, Taylor G, et al. Isolation of highly purified autologous and allogeneic peripheral CD34+ cells using the CliniMACS device. J Hematother 1999; 8: 209-218.
19. Sutherland DR, Anderson L, Keeney M, et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.
20. Boiret N, Kanold J, Fouassier M, et al. CFU-Mk content of immunoselected CD34+ peripheral blood progenitor cells, evaluated with an adapted serum-free methylcellulose assay, is predictive of platelet lineage reconstitution in children with solid tumors. J Hematother Stem Cell Res 2000; 9: 525-534.
21. Beck D, Maritaz O, Gross N, et al. Immunocytochemical detection of neuroblastoma cells infiltrating clinical bone marrow samples. Eur J Pediatr 1988; 147: 609-612.
22. Favrot MC, Frappaz D, Maritaz O, et al. Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow. Br J Cancer 1986; 54: 637-641.
23. Cheung N, Von Hoff D, Strandjord S, et al. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol 1986; 4: 363-369.
24. Tchirkov A, Paillard C, Halle P, et al. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res 2003; 12: 435-442.
25. Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: A multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant 1999; 23: 789-795.
26. Handgretinger R, Greil J, Schurmann U, et al. Positive selection and transplantation of peripheral CD34+ progenitor cells: Feasibility and purging efficacy in pediatric patients with neuroblastoma. J Hematother 1997; 6: 235-242.
27. Handgretinger R, Lang P, Ihm K, et al. Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: Purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 2002; 29: 731-736.
28. Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 1991; 9: 1050-1058.
29. Matthay KK, O'Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: Review of recent Children's Cancer Group results. Eur J Cancer 1995; 31A: 572-575.
30. Matthay KK. Intensification of therapy using hematopoietic stem-cell support for high-risk neuroblastoma. Pediatr Transplant 1999; 3: 72-77.
31. Philip T, Bernard J, Zucker J, et al. High-dose chemoradiotherapy with bone marrow transplantation as consolidation treatment in neuroblastoma: An unselected group of stage IV patients over 1 year of age. J Clin Oncol 1987; 5: 266-271.
32. Haut PR, Cohn S, Morgan E, et al. Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. Biol Blood Marrow Transplant 1998; 4: 38-42.
33. Kasow KA, Sims-Poston L, Eldridge P, et al. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients. Biol Blood Marrow Transplant 2007; 13: 608-614.
34. Diaz MA, Villa M, Madero L, et al. Analysis of engraftment kinetics in pediatric patients undergoing autologous PBPC transplantation. J Hematother 1998; 7: 367-373.
35. Diaz MA, Vicent MG, Garcia-Sanchez F, et al. Long-term hematopoietic engraftment after autologous peripheral blood progenitor cell transplantation in pediatric patients: Effect of the CD34+ cell dose. Vox Sang 2000; 79: 145-150.
36. Mackall CL, Stein D, Fleisher TA, et al. Prolonged CD4 depletion after sequential autologous peripheral blood progenitor cell infusions in children and young adults. Blood 2000; 96: 754-762.
37. Powell JL, Bunin NJ, Callahan C, et al. An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma. Bone Marrow Transplant 2004; 33: 651-657.
38. Hartmann O, Corroller AGL, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs: A randomized, controlled trial. Ann Intern Med 1997; 126: 600-607.
39. Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: Hematologic recovery and costs. A randomized, controlled trial. Ann Intern Med 1997; 126: 600-607.
40. Lode HN, Handgretinger R, Schuermann U, et al. Detection of neuroblastoma cells in CD34+ selected peripheral stem cells using a combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry. Eur J Cancer 1997; 33: 2024-2030.
41. Leung W, Chen AR, Klann RC, et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant 1998; 22: 971-979.
42. Brugger W, Bross KJ, Glatt M, et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
43. Tsang KS, Li CK, Tsoi WC, et al. Detection of micrometastasis of neuroblastoma to bone marrow and tumor dissemination to hematopoietic autografts using flow cytometry and reverse transcriptase-polymerase chain reaction. Cancer 2003; 97: 2887-2897.
44. Donovan J, Temel J, Zuckerman A, et al. CD34 selection as a stem cell purging strategy for neuroblastoma: Preclinical and clinical studies. Med Pediatr Oncol 2000; 35: 677-682.
45. Corrias MV, Haupt R, Carlini B, et al. Peripheral blood stem cell tumor cell contamination and survival of neuroblastoma patients. Clin Cancer Res 2006; 12: 5680-5685.
46. Burchill SA, Kinsey SE, Picton S, et al. Minimal residual disease at the time of peripheral blood stem cell harvest in patients with advanced neuroblastoma. Med Pediatr Oncol 2001; 36: 213-219.
47. Parareda A, Gallego S, Roma J, et al. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma. Oncol Rep 2005; 14: 1021-1027.
48. Ifversen MR, Kagedal B, Christensen LD, et al. Comparison of immunocytochemistry real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma. Int J Oncol 2005; 27: 121-129.
49. Handgretinger R, Leung W, Ihm K, et al. Tumour cell contamination of autologous stem cells grafts in high-risk neuroblastoma: The good news? Br J Cancer 2003; 88: 1874-1877.
50. Brody JD, Goldstein MJ, Czerwinski DK, et al. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009; 113: 85-94.
51. Xie Y, Akpinarli A, Maris C, et al. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207: 651-667.
52. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207: 637-650.
53. Handgretinger R LP, Ihm K, Schumm M, et al. Isolation and transplantation of highly purified autologous peripheral CD34+ progenitor cells: Purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma. Bone Marrow Transplant 2002; 29: 731-736.
54. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapymegatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol 2005; 6: 649-658.
55. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer 2005; 44: 348-357.
56. Philip T, Ladenstein R, Lasset C, et al. 1070 myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer 1997; 33: 2130-2135.
57. Frappaz D, Michon J, Coze C, et al. LMCE3 treatment strategy: Results in 99 consecutivelydiagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol 2000; 18: 468.
58. Kreissman S. A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuroblastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: A Children's Oncology Group study. J Clin Oncol 26: 2008 (May 20 suppl; abstr 10011) 2008: .
59. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children's Oncology Group Study. J Clin Oncol 2009; 27: 1007-1013.